Accelerated Increase in Serum Interleukin-1 Receptor Antagonist Starts 6 Years Before Diagnosis of Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Although interleukin-1 receptor antagonist (IL-1Ra) treatment is associated with improved β-cell function and glycemic control in patients with type 2 diabetes, its role in the development of type 2 diabetes remains unclear. We used repeated measurements to characterize IL-1Ra trajectories in individuals who developed type 2 diabetes. RESEARCH DESIGN AND METHODS: This case-cohort study, nested within the Whitehall II cohort, was based on 335 incident type 2 diabetes cases and 2,475 noncases. We measured serum IL-1Ra levels at up to three time points per individual and estimated retrospective trajectories of IL-1Ra before diabetes diagnosis (case subjects) or end of follow-up (control subjects) using multilevel analysis. Models were adjusted for age, sex, and ethnicity. RESULTS: IL-1Ra levels were already higher in the case than control subjects 13 years before diabetes diagnosis/end of follow-up (mean [95% CI] 302 [290–314] vs. 244 [238–249] pg/ml). In control subjects, IL-1Ra levels showed a modest linear increase throughout the study period. In case subjects, IL-1Ra trajectories were parallel to those in control subjects until 6 years (95% CI 7.5–4.5) before diagnosis and then rose steeply to 399 (379–420) pg/ml at the time of diagnosis (P < 0.0001 for slope difference). Adjustment for BMI and waist circumference as time-varying covariates had little impact on these trajectories. CONCLUSIONS: We show elevated IL-1Ra levels for 13 years and an accelerated increase during the last 6 years before type 2 diabetes diagnosis, indicating the presence of an anti-inflammatory response that may act to counterbalance the metabolic and immunologic disturbances that precede type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most recent attempts to improve diabetes prediction using measurements from genetics and transcriptomics have not shown significant improvements in predictive performance but it is unknown whether serial measurements may decrease variations in non-genetic biomarkers allowing for a more precise estimation of their levels.34–36”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence
Singer, J. D., & Willett, J. B. (2003) · doi:10.1093/acprof:oso/9780195152968.001.0001 · Cited by 10,647
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes
Spranger, J., Kroke, A., Möhlig, M., Hoffmann, K., Bergmann, M. M., Ristow, M., Boeing, H., & Pfeiffer, A. F. H. (2003) · Diabetes · doi:10.2337/diabetes.52.3.812 · Cited by 1,493 · cited 1×
“However, it has been suggested that elevation of only IL-1 may not be sufficient to increase risk of type 2 diabetes; instead, increased IL-1 in combination with elevated levels of other proinflammatory cytokines may be required (28), thus limiting the predictive relevance of the IL-1Ra/IL-1 ratio without consideratio…”
BackgroundRelationship between Adipocyte Size and Adipokine Expression and Secretion
Skurk, T., Alberti-Huber, C., Herder, C., & Hauner, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1055 · Cited by 1,288 · cited 1×
“The finding that the difference in trajectories between case and control subjects could not be explained by obesity is important because adipose tissue is a major producer of IL-1Ra (9,29).”
BackgroundSelf-citationInsulin sensitivity: Modulation by nutrients and inflammation
Schenk, S., Saberi, M., & Olefsky, J. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34260 · Cited by 1,191
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Tabák, A. G., Jokela, M., Akbaraly, T. N., Brunner, E. J., Kivimäki, M., & Witte, D. R. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60619-x · Cited by 898 · cited 3×
“Although the levels of homeostasis model assessment insulin sensitivity (HOMA-2S) and HOMA -cell function (HOMA-2B) differed between incident cases and noncases more than a decade before the diagnosis of type 2 diabetes, a substantial divergence in HOMA trajectories, accompanied by a marked acceleration in the dysregu…”
BackgroundResultInfluentialSelf-citationCohort Profile: The Whitehall II study
Marmot, M., & Brunner, E. (2005) · International Journal of Epidemiology · doi:10.1093/ije/dyh372 · Cited by 788 · cited 1×
“Details regarding study design, baseline characteristics, and source population for the case-cohort study have been described previously (18,19).”
Self-citationThe balance between IL-1 and IL-1Ra in disease
Arend, W. P. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(02)00020-5 · Cited by 721 · cited 1×
“The balance between IL-1 and IL-1Ra has been postulated to be a major determinant of the time course and severity of inflammatory diseases (25,26), and it is conceivable that -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 0 100 200 Non-cases Cases A”
BackgroundBrunner, E. J., Marmot, M. G., Nanchahal, K., Shipley, M. J., Stansfeld, S. A., Juneja, M., & Alberti, K. G. M. M. (1997) · Diabetologia · doi:10.1007/s001250050830 · Cited by 425 · cited 1×
“Details regarding study design, baseline characteristics, and source population for the case-cohort study have been described previously (18,19).”
Self-citationSustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes
Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., & Mandrup-Poulsen, T. (2009) · Diabetes Care · doi:10.2337/dc09-0533 · Cited by 401 · cited 2×
“A double-blind, parallelgroup trial of 70 patients with type 2 diabetes showed that the administration of exogenous IL-1Ra (anakinra) improved glycemia, -cell function, and surrogate markers of systemic inflammation (13,14).”
BackgroundAn immune origin of type 2 diabetes?
Kolb, H., & Mandrup-Poulsen, T. (2005) · Diabetologia · doi:10.1007/s00125-005-1764-9 · Cited by 394
The Role of the Interleukin-1–Receptor Antagonist in Blocking Inflammation Mediated by Interleukin-1
Dinarello, C. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009073431011 · Cited by 373 · cited 2×
“Interleukin-1 (IL-1 ) may be one of the most important immune mediators in this context because this cytokine triggers various proinflammatory events, inhibits -cell function, and promotes -cell apoptosis (7,8).”
BackgroundGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller‐Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15318 · Cited by 363
A urine inhibitor of interleukin 1 activity that blocks ligand binding.
Seckinger, P., Lowenthal, J. W., Williamson, K., Dayer, J. M., & MacDonald, H. R. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.5.1546 · Cited by 345 · cited 1×
“IL-1Ra competitively binds to the IL-1 receptor without inducing a cellular response (7,10,11).”
BackgroundIslet Inflammation in Type 2 Diabetes
Donath, M. Y., Schumann, D. M., Faulenbach, M., Ellingsgaard, H., Perren, A., & Ehses, J. A. (2008) · Diabetes Care · doi:10.2337/dc08-s243 · Cited by 334 · cited 1×
“Interleukin-1 (IL-1 ) may be one of the most important immune mediators in this context because this cytokine triggers various proinflammatory events, inhibits -cell function, and promotes -cell apoptosis (7,8).”
BackgroundBöni-Schnetzler, M., Thorne, J., Parnaud, G., Marselli, L., Ehses, J. A., Kerr-Conte, J., Pattou, F., Halban, P. A., Weir, G. C., & Donath, M. Y. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0396 · Cited by 320 · cited 1×
“We could not test this hypothesis here because the physiological concentrations of IL-1 in individuals without severe inflammatory diseases are so low that they are mostly undetectable with currently available assays (23,27).”
BackgroundAdipose Tissue Is a Major Source of Interleukin-1 Receptor Antagonist
Juge-Aubry, C. E., Somm, E., Giusti, V., Pernin, A., Chicheportiche, R., Verdumo, C., Rohner-Jeanrenaud, F., Burger, D., Dayer, J.-M., & Meier, C. A. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1104 · Cited by 305 · cited 3×
“The finding that the difference in trajectories between case and control subjects could not be explained by obesity is important because adipose tissue is a major producer of IL-1Ra (9,29).”
BackgroundMeier, C. A., Bobbioni, E., Gabay, C., Assimacopoulos-Jeannet, F., Golay, A., & Dayer, J.-M. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8351 · Cited by 287
Leptin modulates β cell expression of IL-1 receptor antagonist and release of IL-1β in human islets
Maedler, K., Sergeev, P., Ehses, J. A., Mathe, Z., Bosco, D., Berney, T., Dayer, J.-M., Reinecke, M., Halban, P. A., & Donath, M. Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305683101 · Cited by 249 · cited 1×
“Differences in secretion of leptin, an adipokine strongly upregulated in obesity that can stimulate IL-1 production and lead to increased IL-1Ra release, may be one of the mechanisms involved (34,35).”
BackgroundHerder, C., Brunner, E. J., Rathmann, W., Strassburger, K., Tabák, A. G., Schloot, N. C., & Witte, D. R. (2009) · Diabetes Care · doi:10.2337/dc08-1161 · Cited by 206 · cited 2×
“Our previous report on IL-1Ra and incident diabetes in a nested case-control study was limited to a single IL-1Ra measurement at study baseline (phase 3) (15) and therefore did not provide information on the time course of IL-1Ra levels preceding diabetes diagnosis.”
BackgroundResultSelf-citationSauter, N. S., Schulthess, F. T., Galasso, R., Castellani, L. W., & Maedler, K. (2008) · Endocrinology · doi:10.1210/en.2007-1059 · Cited by 198 · cited 2×
“In mice, IL-1Ra injections have been demonstrated to protect from diabetes induced by high-fat diet (12).”
BackgroundIL‐1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
Perrier, S., Darakhshan, F., & Hajduch, E. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.10.061 · Cited by 173 · cited 1×
“The balance between IL-1 and IL-1Ra has been postulated to be a major determinant of the time course and severity of inflammatory diseases (25,26), and it is conceivable that -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 0 100 200 Non-cases Cases A”
BackgroundHerder, C., Baumert, J. J., Thorand, B., Köenig, W., de Jager, W., Meisinger, C., Illig, T., Martin, S., & Kolb, H. (2006) · Diabetologia · doi:10.1007/s00125-006-0190-y · Cited by 171
Self-citationBrunner, E. J., Kivimäki, M., Witte, D. R., Lawlor, D. A., Smith, G. D., Cooper, J. A., Miller, M., Lowe, G. D. O., Rumley, A., Casas, J. P., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050155 · Cited by 163 · cited 1×
“Extending the risk factor trajectory approach to inflammatory biomarkers could improve our understanding of the pathogenesis of type 2 diabetes by providing insight into inflammatory changes that may be causally related to disease onset (17).”
BackgroundSelf-citationHigh glucose induces IL-1β expression in human monocytes: mechanistic insights
Dasu, M. R., Devaraj, S., & Jialal, I. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00718.2006 · Cited by 162
Seckinger, P., Williamson, K., Balavoine, J. F., Mach, B., Mazzei, G., Shaw, A., & Dayer, J. M. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.5.1541 · Cited by 140
Maedler, K., Schulthess, F. T., Bielman, C., Berney, T., Bonny, C., Prentki, M., Donath, M. Y., & Roduit, R. (2008) · The FASEB Journal · doi:10.1096/fj.07-101824 · Cited by 99 · cited 1×
“Differences in secretion of leptin, an adipokine strongly upregulated in obesity that can stimulate IL-1 production and lead to increased IL-1Ra release, may be one of the mechanisms involved (34,35).”
BackgroundGlas, R., Sauter, N. S., Schulthess, F. T., Shu, L., Oberholzer, J., & Maedler, K. (2009) · Diabetologia · doi:10.1007/s00125-009-1349-0 · Cited by 90 · cited 1×
“However, data from the anakinra trial (13) as well as preclinical data (12,36) argue strongly against diabetogenic effects of IL-1Ra.”
BackgroundAssociation of IL-1ra and Adiponectin With C-Peptide and Remission in Patients With Type 1 Diabetes
Pfleger, C., Mortensen, H. B., Hansen, L., Herder, C., Roep, B. O., Hoey, H., Aanstoot, H., Kočova, M., Schloot, N. C., & on behalf of the Hvidøre Study Group on Childhood Diabetes (2008) · Diabetes · doi:10.2337/db07-1697 · Cited by 87
Self-citationRuotsalainen, E., Salmenniemi, U., Vauhkonen, I., Pihlajamäki, J., Punnonen, K. R. A., Kainulainen, S., & Laakso, M. (2006) · Diabetes Care · doi:10.2337/dc06-0147 · Cited by 83
Increased plasma interleukin-1 receptor antagonist levels in men with visceral obesity
Cartier, A., Bergeron, J., Poirier, P., Alméras, N., Tremblay, A., Lemieux, I., & Després, J. (2009) · Annals of Medicine · doi:10.1080/07853890903022801 · Cited by 28
Gender-based dimorphic pattern for interleukin-1 receptor antagonist in type 2 diabetes mellitus
Ybarra, J., Lehmann, T. N. O., Golay, A., Juge-Aubry, C. E., Roux-Lombard, P., Dayer, J., & Meier, C. A. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.10.006 · Cited by 17
Alberti (1998) · doi:10.1002/(sici)1096-9136(199807)15:7<539::aid-dia668>3.0.co;2-s
Cited by
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
“, with an accelerated increase in IL-1RA levels before the onset of T2”
BackgroundPrediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
Self-citationAnti-inflammatory effects of exercise: role in diabetes and cardiovascular disease
Pedersen, B. K. (2017) · European Journal of Clinical Investigation · doi:10.1111/eci.12781 · Cited by 617
Bjermo, H., Iggman, D., Kullberg, J., Dahlman, I., Johansson, L., Persson, L., Berglund, J., Pulkki, K., Basu, S., Uusitupa, M., et al. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.030114 · Cited by 490
A review of the evidence for pathogenic mechanisms that may link periodontitis and diabetes
Taylor, J. J., Preshaw, P. M., & Lalla, E. (2013) · Journal of Clinical Periodontology · doi:10.1111/jcpe.12059 · Cited by 425
“A number of clinical trials provide evidence for the utility of cytokine analysis in pre-clinical diagnosis of T2DM (Carstensen et al. 2010) and for cytokine blockade in therapy for T2DM (Larsen et al.”
Background
Metadata
- Authors
- Carstensen, M., Herder, C., Kivimäki, M., Jokela, M., Roden, M., Shipley, M. J., Witte, D. R., Brunner, E. J., & Tabák, A. G.
- Affiliations
- Deutsches Diabetes-Zentrum e.V. (DE)
- Department of Epidemiology and Public Health, University College London, London, U.K.;
- University College London (GB)
- Düsseldorf University Hospital (DE)
- Corresponding author
- Herder, Christian
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-02-25
- Volume
- 59
- Issue
- 5
- Pages
- 1222-1227
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2857902
- OpenAlex
- W2126985857
- Cited by
- 137
- References
- 38
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 7 · 2023: 5 · 2022: 8 · 2021: 9 · 2020: 3 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 11 · 2015: 10 · 2014: 16 · 2013: 16 · 2012: 10
- FWCI
- 9.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- John D. and Catherine T. MacArthur Foundation
- British Heart Foundation (RG/07/008/23674)
- Bupa Foundation
- Health and Safety Executive
- Academy of Finland
- Bundesministerium für Gesundheit
- Novo Nordisk
- National Institutes of Health
- Agency for Healthcare Research and Quality (HS06516)
- Medical Research Council
- Economic and Social Research Council
- National Institute on Aging (AG 13196, R37AG013196, R01AG013196)
- National Heart, Lung, and Blood Institute (R01HL036310)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- interleukin-1 receptor antagonist, type 2 diabetes, prediabetes, serum biomarkers, biomarker trajectories, anti-inflammatory response, inflammation, beta-cell function, Whitehall II cohort
- MeSH terms
- Adult, Diabetes Mellitus, Type 2, Enzyme-Linked Immunosorbent Assay, Female, Humans, Male, Middle Aged, Cohort Studies, Interleukin 1 Receptor Antagonist Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.